Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator
Keyword(s):
Pulmonary arterial hypertension is a chronic and life-threatening disease that if left untreated is fatal. Current therapies include stimulating the nitric oxide–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate axis, improving the prostacyclin pathway and inhibiting the endothelin pathway. Phosphodiesterase type 5 inhibitors, such as sildenafil, and the sGC stimulator riociguat are currently used in the treatment of pulmonary arterial hypertension. This article discusses the similarities and differences between phosphodiesterase type 5 inhibitors and sGC stimulator based on pharmacological action and clinical trials, and considers which is better for the treatment of pulmonary arterial hypertension.
2018 ◽
Vol 15
(2)
◽
pp. 72-76
◽
2020 ◽
Vol 16
(6)
◽
pp. 1009-1016
2016 ◽
2019 ◽
Vol 5
(2)
◽
pp. NP1-NP4
2019 ◽
Vol 13
◽
pp. 175346661986893
◽